Overview of Diapride Plus

Quick Facts

Property	Description
Active Ingredient(s)	Glimepiride, Metformin Hydrochloride
Form	Oral tablet (Fixed-Dose Combination)
Pharmacological Class	Antidiabetic Agents (Sulfonylurea + Biguanide)
Common Use	Management of Type 2 Diabetes Mellitus
Origin	Synthetic

What Type of Medicine is Diapride Plus?

Diapride Plus is a prescription-only oral tablet classified as a synthetic antihyperglycemic agent used for the management of high blood sugar in adults with Type 2 Diabetes Mellitus. It is officially defined as a fixed-dose combination (FDC) product, uniting two distinct active agents with complementary actions, which is a common strategy in chronic disease management. This preparation belongs to the overall group of antidiabetic agents and serves as a method of combination therapy to achieve and sustain blood glucose control in patients whose condition is not adequately managed by a single agent alone.

Composition: A Fixed-Dose Combination of Glimepiride and Metformin

The medication is composed of two distinct active ingredients with complementary mechanisms: Glimepiride and Metformin Hydrochloride. Glimepiride is classified as a sulfonylurea, an agent that works by stimulating insulin release, while Metformin Hydrochloride belongs to the biguanide class. The FDC structure ensures that the two agents are integrated into a single dose base in an oral tablet form, combining the effects of an insulin-releasing agent with a compound that reduces liver glucose output.

Dual Action: The General Benefit of a Combination Therapy

The primary benefit of Diapride Plus is its capacity to address high blood sugar by activating two separate pharmacological strategies simultaneously. This combination therapy is designed to enhance the body's natural insulin response and simultaneously reduce the primary sources of excess blood sugar. This approach is clinically documented to be more effective for achieving improved glycemic control than either drug used alone. Combining these two classes supports more reliable and consistent overall maintenance of targeted blood glucose levels in adult patients with Type 2 Diabetes Mellitus.

What side effects are possible with Diapride Plus?

Possible side effects and safety information

The safety profile for this medication, a combination of Glimepiride and Metformin Hydrochloride, is officially structured by government regulatory agencies based on the frequency and physiological system affected.

Frequency-Classified Adverse Reactions

The most commonly documented adverse reactions are categorized as Very Common (ge 1/10) and often involve the Gastrointestinal system (e.g., diarrhoea, nausea, vomiting, metallic taste). Hypoglycaemia (low blood sugar), an expected effect of Glimepiride, is classified as a Common (ge 1/100 to <1/10) reaction.

Serious Adverse Reactions and Constraints

Regulatory documentation highlights two rare but critical safety concerns. The first is Severe Hypoglycaemia, which may lead to significant neurological effects. The second is Lactic Acidosis, a very rare but life-threatening metabolic emergency primarily associated with the Metformin component [Lactic Acidosis Risk].

Usage is officially restricted in certain populations. Severe Renal Impairment ( eGFR < 30 mL/min/1.73m^2) and Severe Hepatic Impairment are listed as constraints due to the significantly increased risk of Lactic Acidosis and/or severe Hypoglycaemia. The medication is also contraindicated in acute metabolic acidosis and in acute conditions that may cause tissue hypoxia (e.g., severe infection or shock).

Time-Related Safety Patterns

The label notes that Gastrointestinal reactions are frequently observed at the start of treatment and tend to be transient. Conversely, changes in Vitamin B12 serum levels may be associated with long-term exposure to the Metformin component.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Diapride Plus is a medical emergency characterized by the severe, life-threatening risks associated with its two components: hypoglycemia (low blood sugar) from Glimepiride and lactic acidosis from Metformin. Both conditions constitute a medical emergency and require hospitalization.

Hypoglycemia Manifestations and Action

Overdose on the Glimepiride component can result in severe and prolonged hypoglycemia. Documented manifestations include confusion, slurred speech, fast heartbeat, and tremor, potentially progressing to seizures and unconsciousness (coma). Due to the risk of recurrent low blood sugar, hospital monitoring for 24 hours or more is required. Treatment involves the prompt administration of glucose, often via intravenous infusion for severe cases.

Lactic Acidosis Manifestations and Action

Overdose leading to Metformin accumulation is associated with the life-threatening complication of lactic acidosis. Early signs are often nonspecific, such as general malaise, muscle pain (myalgias), or severe respiratory distress. Lactic acidosis must be treated in a hospital setting. No specific antidote is known; however, prompt hemodialysis is recommended to correct the acidosis and remove accumulated Metformin.

When to Seek Urgent Help

You must seek immediate medical attention for any suspected overdose or for any symptoms of hypoglycemia or lactic acidosis. Contact emergency services immediately if the patient has collapsed or cannot be awakened. Elderly patients and individuals with pre-existing hepatic or renal impairment are documented to be at increased risk for these severe outcomes.

Therapeutic Uses of Diapride Plus

What Diapride Plus Treats: Main Uses and Benefits

This fixed-dose combination medication is commonly used to help with the long-term management of Type 2 Diabetes Mellitus (T2DM) in adults. It is applied in clinical settings where the condition requires additional support when single-agent therapy is no longer sufficient to manage blood sugar targets. This medication is considered relevant for patients experiencing conditions characterized by periods of heightened symptoms related to inadequate blood sugar regulation.

The primary therapeutic benefit is to provide intensified support to the body's glucose-regulating system, and may assist patients in managing the challenge of maintaining target blood sugar goals. This combination helps address symptom clusters related to systemic imbalance, including high Fasting Plasma Glucose (FPG), post-meal glucose (PPG), and elevated Glycated Hemoglobin (HbA1c) levels.

Quick Fact: Supportive Management

This supportive management strategy helps to manage the long-term risk associated with microvascular changes. By stabilizing these symptoms related to heightened physiological activity, the medication contributes to improved comfort and provides support that helps ease the overall symptom burden over time.

Regulatory References

Health Canada (Glimepiride/Metformin Combination)

Eligibility and Restrictions for Use

Who Can and Cannot Use Diapride Plus?

This fixed-dose combination of Glimepiride and Metformin is officially restricted to adults with Type 2 Diabetes Mellitus whose blood sugar levels are not adequately controlled by either agent alone. Eligibility is strictly defined by regulatory documents, which list several absolute contraindications and restrictions.

Absolute Contraindications

Use is prohibited for patients with:

Severe renal impairment (e.g., eGFR below 30 mL/min/1.73 m^2)
Type 1 Diabetes Mellitus or Diabetic Ketoacidosis (DKA)
Acute or chronic metabolic acidosis or acute conditions causing tissue hypoxia (e.g., septicemia, shock)
Severe hepatic failure
Known hypersensitivity to Glimepiride, Metformin, other sulfonylureas, or sulphonamides

Age and Physiological Restrictions

Population	Eligibility Status (Regulatory Wording)
Children and Adolescents (under 18)	Safety and efficacy are not established
Older Adults (over 65)	Use requires caution and close renal function monitoring
Pregnancy	Not recommended (Insulin is often preferred)
Breastfeeding	Not recommended

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for this fixed-dose combination details specific interaction patterns, primarily focusing on pharmacokinetic and pharmacodynamic effects.

Formally Contraindicated and Restricted Combinations:

Iodinated Contrast Agents are formally contraindicated for co-administration. Diapride Plus must be temporarily discontinued at the time of or prior to the procedure and withheld for 48 hours subsequent to the procedure. This restriction addresses the severe risk of Metformin accumulation and subsequent Lactic Acidosis.
Excessive alcohol intake is documented to potentiate the effect of Metformin on lactate metabolism, significantly increasing the risk of Lactic Acidosis.

Pharmacokinetic Interactions:

The elimination of the Metformin component is affected by Cationic Drugs (e.g., Cimetidine, Ranolazine), which reduce Metformin renal clearance, leading to increased exposure and accumulation.
The Glimepiride component, metabolized by the CYP2C9 enzyme, interacts with certain agents. CYP2C9 Inhibitors (e.g., Fluconazole) increase Glimepiride plasma concentration, which may potentiate the blood-glucose-lowering effect. Conversely, CYP2C9 Inducers (e.g., Rifampicin) may weaken the effect by reducing exposure.

Pharmacodynamic Interactions:

A range of medicinal products have documented additive or opposing effects on blood sugar. Co-administration with Hypoglycemia-Potentiating Agents (e.g., other antidiabetics, Salicylates) increases the risk of an additive effect. Conversely, agents such as Glucocorticoids and Diuretics may weaken the blood-glucose-lowering effect.

Mechanism of Action

How Diapride Plus Works

Diapride Plus is characterized by the modulation of two distinct physiological processes: the capacity of beta-cells to release insulin and the rate of hepatic glucose production.

Targeting beta-Cell Secretion and Insulin Mobilization

The Glimepiride component initiates its action by binding to the ATP-sensitive potassium channel ( KATP channel) on the pancreatic beta-cell membrane, leading to its closure. This molecular blockade causes the cell membrane to depolarize, which subsequently opens voltage-gated Ca^2+ channels. The rapid influx of Ca^2+ triggers the exocytosis of insulin into the circulation, resulting in the mobilization and release of stored hormone.

Modulating Hepatic Glucose Production via AMPK

Metformin operates within the cellular energy sensing pathway by mildly inhibiting mitochondrial Complex I, which increases the AMP/ ATP ratio and activates AMPK. The activated AMPK then suppresses the gene expression and activity of key liver enzymes required for gluconeogenesis. This metabolic modulation decreases the production and output of glucose by the liver.

Mechanistic Synergy and Dual Action

The agents operate synergistically by modulating two distinct, sequential physiological pathways. Glimepiride initiates the acute insulin secretion sequence, while Metformin, through its AMPK-mediated action, simultaneously decreases the major source of circulating glucose and enhances insulin responsiveness in peripheral tissues. This coordination results in a joint physiological regulation of systemic glucose concentration across production and clearance pathways.

Dosage and Administration Information

Official Administration Guidelines: Diapride Plus (Glimepiride/Metformin Hydrochloride)

Route and Administration

The medication is administered orally (by mouth). Tablets must be swallowed whole with liquid and must not be crushed or chewed to preserve the integrity of the sustained-release/prolonged-release formulation. Diapride Plus is typically taken once daily or twice daily, immediately before or during a main meal, such as breakfast.

Dosing and Monitoring Rules

The dosage must be individualized based on the patient’s existing therapy and their desired blood glucose levels, always aiming for the lowest effective dose. The maximum daily dose is 8 mg for glimepiride and 2000 mg for metformin (sustained release). A forgotten dose must not be corrected by taking a double or larger dose subsequently.

Procedural Condition	Required Action
Missed Dose	Do not take an extra dose to make up for the missed one.
Renal Impairment	Not for use if eGFR is below 30 mL/min/1.73 m^2. Dosing requires adjustment if eGFR is between 30-59 mL/min/1.73 m^2.
Surgical/Contrast Procedures	The medication must be temporarily discontinued before or at the time of any intravascular iodinated contrast procedure or major surgery. It should not be restarted until 48 hours after the procedure, provided renal function is evaluated and found to be normal.

Population-Specific Use

Use in pediatric patients has not been established. Caution is required when prescribing to geriatric patients due to the need for regular monitoring of kidney function.

Recent Clinical Evidence

Research evidence / Overview of studies for Diapride Plus

Evidence for Use in Type 2 Diabetes Mellitus

Research into the Glimepiride and Metformin combination has been largely conducted using Randomized Controlled Trials (RCTs). These are studies where patients are assigned randomly to receive either the combination medication or a comparison treatment. These studies were applied in research contexts involving fluctuating or unstable symptoms in adult patients with Type 2 Diabetes Mellitus (T2DM) whose condition was not well managed by taking a single medication. Systematic reviews and meta-analyses, which pool data from several trials, also contribute to the evidence landscape for this combination.

The main focus of these trials was to measure changes in biomarkers of glycemic control, which track systemic or functional imbalance. Specifically, research monitored changes in the key glycemic biomarkers, such as Glycated Hemoglobin (HbA1c), Fasting Plasma Glucose (FPG), and glucose levels after meals (PPG). Studies reported observations where patients on the combination therapy reached defined HbA1c targets, and these findings were studied against comparator medications like monotherapy. Findings also reported changes in HbA1c and FPG values over the study period, providing insight into blood sugar patterns observed in the studied populations.

The Scope of Study Outcomes Examined

Beyond the primary glucose markers, research also examined several secondary outcomes. These secondary outcomes included changes in serum lipid profiles (such as Total Cholesterol and Triglycerides) and Body Weight/Body Mass Index (BMI). These measurements were used in research examining patterns in other factors related to metabolic health. Research highlights changes measured during the study period, reporting that observed patterns in certain lipid markers were described in some studies, and studies reported patterns in body weight described as weight-neutral or associated with modest changes.

What is Still Uncertain About Diapride Plus Research

While the evidence landscape is substantial, certain gaps and limitations remain. Research indicates that the primary outcomes measured in many key trials are surrogate endpoints, meaning they track biomarkers like HbA1c rather than hard clinical outcomes, such as reduction of macrovascular events. Long-term effects on these definitive clinical outcomes are not fully established.

Furthermore, comparative evidence is lacking for a direct comparison between the two forms of combination therapy: taking the single fixed-dose combination tablet versus taking the two components as separate pills. As with all clinical research, findings describe group patterns, not individual predictions, and research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Diapride Plus (FAQ)

Q: How quickly should Diapride Plus start lowering blood sugar?

Official information indicates that the Glimepiride component, which stimulates insulin release, typically reaches its maximum level in the blood about 2.5 hours after oral administration. This indicates the Glimepiride component begins to act in the body shortly after administration, with the goal of supporting blood sugar management.

Q: Is it better to take Diapride Plus in the morning or at night?

Regulatory documents state that this medication is typically administered once daily with or immediately before the first main meal of the day, such as breakfast. The regulatory guidance to take the dose with food is intended to help minimize potential gastrointestinal side effects and support the action of the Glimepiride component.

Q: Is it normal to feel a little dizzy when first starting Diapride Plus?

Dizziness is a known symptom associated with hypoglycemia (low blood sugar), which is listed as a common side effect of this medication, especially as the body adjusts to treatment. The potential symptoms of low blood sugar (hypoglycemia) may include dizziness, lightheadedness, confusion, or headache. This risk is acknowledged in the product information.

Q: Is fatigue a common side effect reported by Diapride Plus users?

While fatigue itself may not be listed as a primary side effect, tiredness or lack of energy is a potential symptom associated with hypoglycemia. Furthermore, long-term use may be linked to decreased Vitamin B12 levels, and low B12 levels are sometimes associated with fatigue.

Q: How often do patients need lab work when taking Diapride Plus?

Official warnings and precautions state that kidney function must be checked before starting this medication. Monitoring should be done at intervals determined by the prescriber, often at least annually according to official guidance. Regular monitoring of Vitamin B12 serum levels is also advised during long-term treatment.

Q: Does taking Diapride Plus require special monitoring for liver issues?

The medication is strictly contraindicated (prohibited) in patients with severe hepatic failure due to the significantly increased risk of lactic acidosis. Because of this restriction, careful monitoring of liver status may be necessary during treatment.

Q: Does Diapride Plus interact with blood pressure medications?

Yes, official regulatory information confirms interactions with certain drug classes. For instance, medications such as Diuretics or Glucocorticoids may weaken the blood-glucose-lowering effect of Diapride Plus. It is important for patients to discuss all co-administered medications with a healthcare professional.

Q: Are headaches a temporary or long-term side effect of Diapride Plus?

Regulatory reports from clinical trials list headache as a common adverse reaction. Headaches are also a possible symptom of hypoglycemia (low blood sugar). If you experience persistent or severe headaches, it is important to consult with a healthcare professional.

Q: Does Diapride Plus have a generic equivalent?

Yes. According to regulatory registries, fixed-dose combination products containing the active ingredients Glimepiride and Metformin are available in generic versions.

Q: What are the long-term effects of taking Diapride Plus?

Long-term regulatory data indicates that the Metformin component can be associated with a decrease in Vitamin B12 serum levels. Additionally, official clinical trials have not yet established conclusive evidence that this combination reduces the risk of long-term macrovascular events.

Q: Does Diapride Plus help with insulin resistance?

The Metformin component of Diapride Plus works in part by modulating the cellular energy pathway. This action helps to increase the sensitivity of the body's peripheral tissues to insulin (insulin responsiveness), thereby addressing one aspect of insulin resistance.

Q: What happens if Diapride Plus is stopped suddenly?

Stopping the medication abruptly can lead to a rebound increase in blood glucose levels (hyperglycemia) because the drug's effect is removed. Hyperglycemia can cause the symptoms and severe complications associated with uncontrolled diabetes. Treatment should not be stopped abruptly without consulting a healthcare professional.

Q: Does Diapride Plus affect energy levels?

Official documentation lists adverse reactions that can impact energy. Symptoms such as fatigue and general weakness are often associated with episodes of hypoglycemia (low blood sugar), which is a common side effect of the Glimepiride component.

Q: Are there different strengths of Diapride Plus available?

Yes. Official product information confirms that this fixed-dose combination product is manufactured and available in multiple strengths containing different amounts of the Glimepiride and Metformin components.

Q: Can Diapride Plus be taken with or without food?

Regulatory guidelines state that the medication must be administered with or immediately before a meal (such as breakfast). This requirement is intended to minimize potential gastrointestinal side effects and ensure the drug works as intended.

Q: Can pregnant or breastfeeding women take Diapride Plus?

The medication is not recommended for women who are pregnant because insulin is typically preferred for blood sugar control during pregnancy. It is also not recommended during breastfeeding as it is unknown whether the Glimepiride component passes into breast milk.

Q: Are there any specific foods that enhance or reduce the effect of Diapride Plus?

Official warnings strongly advise against excessive alcohol consumption while taking Diapride Plus. Excessive alcohol use can significantly raise the risk of a serious metabolic complication called lactic acidosis, as well as increase the risk of hypoglycemia. No other specific foods are generally highlighted as major interactions.

Q: What is the main benefit of having two different medicines combined in Diapride Plus?

The key advantage, as noted in official sources, is that the two agents act by two complementary mechanisms—stimulating insulin release and reducing liver glucose production. This combined approach is designed to support better and more consistent blood glucose control than using either drug alone.

Q: Are there any known interactions between Diapride Plus and herbal supplements?

While specific herbal products are not universally listed in regulatory documents, it is officially recommended that patients inform their healthcare professional about all co-administered medications, vitamins, and herbal supplements. Disclosing all supplements is important because of the potential for interactions that could affect how the medication works.

Q: Are there any studies comparing Diapride Plus to other combination therapies?

Yes. Official clinical study summaries indicate that trials have been conducted comparing the Glimepiride/Metformin fixed-dose combination to other dual therapies, such as Glimepiride when combined with other classes of antidiabetic agents.

How should Diapride Plus be stored and disposed of?

How to Store and Dispose of Diapride Plus

Storage Requirements

Diapride Plus (Glimepiride and Metformin Hydrochloride tablets) must be stored under specific conditions to maintain stability and effectiveness. The medicine must be kept at a temperature that does not exceed 30 C and should be protected from moisture and excessive heat. It is a mandatory requirement to store the tablets in their original container and keep the container tightly closed.

Child-Safety and Disposal

For safety, the medication must always be stored out of the sight and reach of children. Unused or expired tablets should not be disposed of via wastewater or household trash. Disposal must be carried out according to local regulations, often requiring return to a pharmacy or designated collection program.

Diapride Plus